Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis
Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis (REVAMP-Sepsis)
Who can join
All ages · All sexes
Full eligibility criteria
Patient Inclusion Criteria: * Admitted to one of the participating PICUs during the study period Patient Exclusion Criteria: * None Clinician Inclusion Criteria: 1. PICU prescribing clinician (including attending physicians, fellows, residents, nurse practitioners, and physician assistants) OR sepsis stakeholder (leader of sepsis quality improvement work, medical director) at one of the participating sites at the time the survey is deployed 2. Age ≥ 18 years old 3. Employed by one of the participating sites Clinician Exclusion Criteria: 1. Volunteers or other non-employee hospital staff 2. Limited English proficiency
About the study
The goal of this quasi-experimental interventional study is to determine the effectiveness of a multifaceted stewardship intervention in reducing overall vancomycin use in five tertiary care Pediatric Intensive Care Units (PICU).
There are two groups of subjects in this study: PICU clinicians/sepsis stakeholders and patients admitted to one of the participating PICUs during the study period. The intervention will at a minimum include:
* Implementation of a clinical guideline indicating when vancomycin should and should not be used * Unit-level feedback on overall vancomycin use within and across centers * Clinician education.
What is being tested
- Multifaceted de-implementation strategy to reduce vancomycin overuse (behavioral)
Sponsor: Children's Hospital of Philadelphia · Participants: 52,500 · Started: Aug 21, 2023
Contact the study team
- Kathleen Chiotos, MD, MSCE · Phone: 215-590-5505
- Kai Inoki, MPH · Phone: 215-590-5505
Official record on ClinicalTrials.gov — NCT05975671
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.